Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate safety by collecting serious adverse events in
subjects with moderately to severely active rheumatoid arthritis who are unable to obtain
etanercept and who have failed one or more prior disease-modifying antirheumatic drugs
(DMARDs).